66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

Advance Care Planning (ACP) & Legal Instruments

Advance care planning is a proactive, iterative communication process wherein patients identify their values, define personal goals for future medical care, and designate trusted surrogate decision-makers. Effective ACP conducted in primary care reduces unwanted invasive interventions, decreases family bereavement trauma, and improves concordance between patient wishes and end-of-life care.

The Core Legal & Clinical Documents

                   ADVANCE CARE PLANNING INSTRUMENTS IN CLINICAL PRACTICE

   Document / Order              Key Characteristics & Legal Authority                 Clinical Application & Setting
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Durable Power of              • Appoints a legal Healthcare Proxy / Surrogate       • Operates ONLY when the patient
   Attorney for Healthcare       • Empowered to make medical decisions if and when       lacks decision-making capacity.
   (DPOA-HC / Healthcare Proxy)    the patient loses decision-making capacity.         • Applies across all care settings.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Living Will                   • Instructional directive specifying treatments       • Activated only in terminal illness,
                                   desired or refused (e.g., mechanical ventilation,    end-stage condition, or persistent
                                   CPR, hemodialysis, artificial nutrition/hydration).  vegetative state with lost capacity.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   POLST / MOLST                 • ACTIONABLE, SIGNED MEDICAL ORDERS                   • Designed for seriously ill or frail
   (Physician / Medical Orders     (Translates patient goals into immediate medical      patients with limited life expectancy.
   for Life-Sustaining Treatment)  orders: CPR status, intubation, feeding tubes).     • Legally binding on EMS, ERs, nursing
                                 • Signed by licensed clinician AND patient/proxy.       homes, and acute care hospitals.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Ethical Standards for Surrogate Decision-Making

When a patient loses medical decision-making capacity, the surrogate decision-maker must adhere to a strict ethical hierarchy:

1. Substituted Judgment Standard (Primary Standard): The surrogate must decide based on what the patient WOULD HAVE chosen if they were still able to speak for themselves, reconstructing the patient's explicit statements, personal philosophy, religious beliefs, and previous values.
2. Best Interests Standard (Secondary Standard): Used ONLY when the patient's personal wishes are unknown or cannot be ascertained (e.g., an individual who has been cognitively impaired since childhood). The surrogate and medical team decide what a reasonable person would choose to maximize net benefit and minimize pain and suffering.

Palliative Care vs. Hospice Care

Distinguishing palliative care from hospice is an essential competency for board certification:

• Palliative Care: Specialized medical care for people living with a serious, life-limiting illness. Focused on providing relief from the symptoms, pain, and physical/psychological stress of the condition.
  • Timing: Appropriate at ANY age and at ANY stage of a serious illness.
  • Concurrent Care: Delivered SIMULTANEOUSLY with curative, life-prolonging, disease-modifying therapies (e.g., palliative care concurrent with adjuvant chemotherapy, radiation, hemodialysis, or heart failure GDMT).
• Hospice Care: A specialized model and Medicare/insurance benefit of comprehensive comfort-focused care delivered at the end of life.
  • Eligibility Criterion: Two physicians (the hospice medical director and attending physician) must certify that the patient has a terminal illness with a life expectancy of $\le 6$ months if the disease follows its natural course.
  • Treatment Intent: The patient and family elect to forego curative, disease-directed, or life-prolonging interventions in favor of comfort, symptom management, and dignity.
  • Interdisciplinary Coverage: Encompasses medical care, nursing, 24/7 on-call coverage, pharmaceuticals for symptom control, medical equipment (hospital bed, oxygen), social work, chaplaincy, and 13 months of bereavement support for surviving family members.

End-of-Life Symptom Management: Pain

Pain occurs in over 70–80% of patients with advanced cancer and non-cancer terminal illnesses. The WHO analgesic ladder provides a framework: mild pain (acetaminophen, NSAIDs), mild-to-moderate pain (weak opioids), and moderate-to-severe pain (potent full opioid agonists).

Equianalgesic Dosing & Opioid Conversions

When rotating opioids due to refractory pain, adverse effects, or transitioning between oral and intravenous routes, precise equianalgesic calculations are required:

                   OPIOID EQUIANALGESIC CONVERSION MATRIX

   Opioid Drug                  Oral Dosing (mg)                 Parenteral (IV/SC) Dosing (mg)
   ════════════════════════════════════════════════════════════════════════════════════════════
   Morphine                     30 mg                            10 mg  (1:3 IV-to-Oral Ratio)
   ────────────────────────────────────────────────────────────────────────────────────────────
   Oxycodone                    20 mg                            --     (No IV in US)
   ────────────────────────────────────────────────────────────────────────────────────────────
   Hydromorphone (Dilaudid)     7.5 mg                           1.5 mg (1:5 IV-to-Oral Ratio)
   ────────────────────────────────────────────────────────────────────────────────────────────
   Fentanyl                     --                               100 mcg (0.1 mg) IV
   (Transdermal Patch)          (25 mcg/hr transdermal patch ≈ 60–90 mg oral morphine equivalents/day)
   ────────────────────────────────────────────────────────────────────────────────────────────
   Methadone                    Variable (Non-linear conversion due to long t1/2 and NMDA activity)
   ════════════════════════════════════════════════════════════════════════════════════════════

• Incomplete Cross-Tolerance Rule: When rotating from one opioid to another due to intolerable side effects or uncontrolled pain, calculate the equianalgesic dose and REDUCE by 25% to 50% to account for incomplete cross-tolerance across opioid receptor subtypes.
• Breakthrough Pain Prescription: For patients on round-the-clock baseline opioids, prescribe an immediate-release short-acting opioid for breakthrough pain:
  • Dose: 10% to 15% of the total 24-hour baseline oral morphine equivalent (OME) requirement.
  • Frequency: Prescribed every 1 to 2 hours PRN orally, or every 15 to 30 minutes IV.

Renal Impairment & Opioid Neurotoxicity

Renal failure fundamentally dictates safe opioid selection in palliative care:

• Morphine: Metabolized by the liver into Morphine-6-glucuronide (M6G) (potent analgesic and respiratory depressant) and Morphine-3-glucuronide (M3G) (non-analgesic, neurotoxic). Both metabolites are eliminated 100% by the kidneys. In renal failure (eGFR $<30\text{ mL/min}$), M3G and M6G accumulate massively, triggering severe opioid neurotoxicity: multifocal myoclonus, tactile allodynia, hyperalgesia, delirium, seizures, and respiratory arrest.
• Oxycodone & Hydromorphone: Hydromorphone is metabolized to hydromorphone-3-glucuronide (H3G; neurotoxic). It can be used with extreme caution and reduced doses in mild-to-moderate renal disease, but accumulates in severe CKD.
• SAFEST OPIOIDS IN ADVANCED RENAL FAILURE / DIALYSIS:
  1. Fentanyl: Metabolized entirely by hepatic CYP3A4 to inactive metabolites (norfentanyl) with zero active renal metabolites. It is the preferred opioid in acute renal failure or dialysis.
  2. Methadone: Hepatically metabolized and eliminated primarily via feces/biliary system; no active renal metabolites. Safe in renal failure, but requires expert monitoring due to variable half-life (15–120 hours) and QTc prolongation.

The Cardinal Rule: Opioid-Induced Bowel Dysfunction

[!CRITICAL] Opioid-Induced Constipation (OIC) Prophylaxis Opioids bind peripheral mu-opioid receptors in the myenteric and submucosal plexuses of the gastrointestinal tract, causing tonic circular muscle contraction, halting propulsive peristalsis, and increasing fluid absorption from stool.

• Tolerance to constipation NEVER develops (unlike tolerance to nausea, sedation, or pruritus, which resolves within 3–7 days).
• MANDATORY CO-PRESCRIPTION: Every patient started on round-the-clock opioids MUST SIMULTANEOUSLY BE PRESCRIBED A PROPHYLACTIC BOWEL REGIMEN.
• First-Line Regimen: A stimulant laxative (Senna 1–2 tablets PO daily or bisacodyl 10 mg PO daily) combined with an osmotic laxative (Polyethylene Glycol [PEG 3350] 17 g daily).
• Clinical Trap: Docusate sodium stool softener monotherapy is completely INEFFECTIVE in randomized clinical trials; it acts as a weak detergent and does not stimulate the propulsive peristalsis halted by opioids.
• Refractory OIC: Peripherally acting mu-opioid receptor antagonists (PAMORAs; e.g., methylnaltrexone 12 mg subcutaneous injection). Methylnaltrexone does not cross the blood-brain barrier, immediately inducing bowel evacuation within 30–60 minutes without reversing central analgesia or precipitating opioid withdrawal.

End-of-Life Symptom Management: Dyspnea, Secretions & Delirium

1. Refractory Dyspnea (Air Hunger)

Dyspnea is among the most terrifying symptoms experienced by patients with end-stage COPD, heart failure, ALS, and lung cancer. Dyspnea represents a mismatch between central motor respiratory drive and afferent mechanical feedback from chest wall mechanoreceptors.

• Systemic Opioids — First-Line Pharmacotherapy:
  • Mechanism: Low-dose opioids (e.g., oral morphine 5 to 10 mg PO every 3–4 hours PRN, or 2.5–5 mg IV) blunt central medullary sensitivity to hypercapnia and hypoxia, decrease central perception of breathlessness, and alleviate secondary anxiety.
  • Clinical Safety: Extensive clinical trials demonstrate that carefully titrated low-dose opioids relieve dyspnea WITHOUT causing respiratory depression or shortening survival in terminally ill patients.
• Bedside Fan Therapy (Non-Pharmacological First-Line):
  • Directing a portable electric fan blowing cool air across the patient's cheek, nose, and mouth stimulates mechanoreceptors in the ophthalmic (V1) and maxillary (V2) divisions of the trigeminal nerve.
  • This sends inhibitory afferents to the brainstem respiratory center, significantly decreasing the sensation of air hunger. It is as effective as supplemental oxygen in non-hypoxemic patients.
• Supplemental Oxygen Restrictions:
  • Indicated ONLY if objective hypoxemia is documented ($S_aO_2 < 88-90%$).
  • In non-hypoxemic patients, high-flow supplemental oxygen provides zero symptom relief compared to room air and causes nasal mucosal crusting, drying, and epistaxis.

2. Terminal Secretions ("The Death Rattle")

In the final 24 to 48 hours of life, severely somnolent, comatose, or dying patients lose their swallowing and cough reflexes. Saliva, mucus, and bronchial secretions pool in the hypopharynx and upper airways, creating oscillating, coarse, noisy respirations during inspiration and expiration.

• Communication Pearl: Terminal secretions rarely cause distress to the unconscious patient, but cause intense emotional anguish to bedside family members who mistake it for choking or suffocating. Education and reassurance are paramount.
• First-Line Non-Pharmacologic Action: Reposition the patient into a lateral side-lying or semi-prone position, elevating the head of the bed to promote passive postural gravitational drainage. Perform gentle oral hygiene with moist foam swabs.
• AVOID AGGRESSIVE TRACHEOPHARYNGEAL SUCTIONING: Deep suctioning induces gagging, coughing, bronchospasm, mucosal hemorrhage, and agitation without clearing hypopharyngeal pooling.
• Anticholinergic / Antimuscarinic Pharmacotherapy:
  • Glycopyrrolate (Robinul): 0.2 to 0.4 mg SC or IV every 4 hours PRN (or continuous infusion). PREFERRED AGENT because it is a quaternary ammonium compound with high water solubility that DOES NOT CROSS THE BLOOD-BRAIN BARRIER. It treats secretions without causing central anticholinergic delirium or sedation.
  • Scopolamine: Transdermal patch (1.5 mg replaced every 72 hours) or subcutaneous injection (0.4 mg q4h). Crosses the blood-brain barrier; provides sedation but carries a significant risk of worsening central delirium.
  • Hyoscyamine: 0.125 to 0.25 mg sublingually or orally every 4 hours.

3. Terminal Delirium & Agitation

Hyperactive delirium (restlessness, purposeless plucking at sheets, hallucinations, vocalizations) develops in over 80% of dying individuals in their final days.

• Reversible Etiology Assessment: Rapidly assess for easily remediable triggers: acute urinary retention (place urinary catheter), severe fecal impaction, unmanaged pain, or medication toxicity.
• Pharmacologic Management:
  • Haloperidol (First-Line): 0.5 to 2.0 mg PO, SC, or IV every 2 to 4 hours PRN. A high-potency dopamine antagonist with minimal sedating or anticholinergic effects.
  • Atypical Antipsychotics: Olanzapine (2.5–5 mg PO/ODT) or Quetiapine (25–50 mg PO) for mild agitation with intact swallowing.
• Refractory Agitation & Palliative Sedation:
  • When delirium or distress is intractable and refractory to all targeted medical interventions, palliative sedation may be initiated following multidisciplinary palliative consultation and informed family consent.
  • Midazolam continuous subcutaneous or IV infusion (titrated from 0.5–2 mg/hr) or propofol is administered to relieve intractable suffering, without the intent to hasten death.